"Pharmaceutical Speed Reading" Consino today landed on the board FDA to accelerate the approval of DMD innovative therapies.

August 13, 2020 / Medical Information List: National Health Care Commission released: primary health care institutions performance appraisal standards; F2G completed a total of 60 million U.S. dollars in new round of financing; AbbVievetoclax joint Aza celline first-line treatment AML Phase III clinical significantly extended OS; regenerative breakthroughfirst in class single resistance by the FDA priority review ... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief Issued by the National Health and Health Commission: The National Health Care Commission issued the "Guidance on Strengthening performance appraisal of primary health care institutions (Trial)", the performance appraisal of primary medical institutions has a unified national standard, by the service provision, comprehensive management, sustainable development and satisfaction evaluation and other four aspects of 42 indicators, including academic level, Chinese medicine services, electronic file rate into an important indicator.
(National Health and Health Commission) three provinces jointly with the volume of procurement 12, Guizhou Province, the centralized procurement platform of medicine released "Guizhou Provincial Medical Security Bureau Chongqing Health Security Bureau, Hainan Provincial Health Security Bureau, the crown pulse expansion balloon joint belt procurement documents (draft for comments).
shows that Guizhou Province, Chongqing City, Hainan Province joint procurement area appointed representatives to form a joint procurement office, on behalf of 3 provinces and cities medical institutions to implement joint volume procurement.
the daily work and implementation of this volume procurement by the Guizhou Provincial Medical Security Bureau.
(Guizhou Province pharmaceutical centralized procurement platform) retail pharmacies: autumn and winter epidemic prevention and control requirements came to Heilongjiang Drug Administration issued on the 12th "on the continued strengthening of pharmacy sales "anti-fever cough antiviral" drug real-name registration supervision work notice", clearly to further improve pharmacy sales" three categories Drug "real name registration work of the importance of the understanding, to overcome paralysis thought, war-weary mood, lucky psychology, relaxed mentality, strengthen supervision, promote pharmacies to improve the epidemic prevention and control "sentinel" sensitivity, so that prevention and control loopholes re-screening, prevention and control focus re-reinforcement, prevention and control work re-implemented.
(Heilongjiang Drug Administration) announced: This year's professional pharmacist examination cancelled the Beijing People's Social Bureau issued "on the Beijing area 2020 professional and technical personnel professional qualification examination into the next year to carry out the notice", mentioned that according to the needs of epidemic prevention and control work, after research decision, Beijing area 2020 first-class builders and other professional and technical personnel professional qualification examination and into the 2021 unified organization, which includes the professional pharmacist examination.
(Beijing People's Social Bureau) Part 2 produced by observation Concino today landed on the science board became the first "A-H" vaccine unit Concino today successfully landed on the science board, became the first "A-H" vaccine unit.
Kong Concino's public offering of 24.8 million shares at a price of 209.71 yuan.
that the funds raised will be used for the second phase of production base construction, vaccine research and development, vaccine traceability, cold chain logistics system and information system construction and supplementary working capital.
(Sina Pharmaceutical News) Celleron and Roche signed a license agreement on the 12th, Celleron announced a licensing agreement with Roche, the latter cancer research drug emactuzumab clinical development, production and commercialization of the global exclusive rights, is expected to complete all handovers by the end of 2020.
the two companies did not disclose the amount of the deal.
(Sina Pharmaceutical News) the chairman of a well-known arms company resigned Lidman issued a notice on the 12th, the board of directors of the enterprise on August 11, 2020 received a written resignation report from the chairman of the board of directors, Mr. Lin Wei.
reasons for the transfer of work, Mr. Lin requested to resign as chairman and director of the company, and at the same time resigned as convenor of the strategic committee of the board of directors, and resigned from any position of the company.
(Lidman Announcement) F2G completed a new round of financing totalling $60 million F2G announced the completion of a new round of financing totalling $60 million.
round of financing is led by Cowen Healthcare Investments, which also includes Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences.
funding will be used to advance clinical testing of the company's main product, olorofim, and the expansion of its existing team.
BridgeBio announced a partnership with UTO Bio, bridgeBio announced a partnership with UTO Bio to expand its pipeline to China.
terms of the agreement, Otto Bio will receive commercial interests in China and designated Asian markets and participate in the clinical development of infigratinib and BBBP-398.
same time, Otto Bio has been given priority over BridgeBio's more than 20 pipeline products in China and other major Asian markets.
(Pharmaceutical Mission) Part 3 Drug News AbbVievenetoclax Joint Aza Cytosine First-Line Therapy AML Phase III ClinicalLy Extended OS Local Time 12, AbbVie announced the results of Phase 3 clinical trial VIALE-A published in the New England Journal of Medicine.
the study evaluated the efficacy and safety of venetoclax in combination with azatase, in patients with new diagnosed acute myeloid leukemia (AML) without chemotherapy, and in patients who could not withstand traditional high-intensity chemotherapy.
results showed that venetoclax dual-drug therapy significantly extended total survival (OS) and reduced the risk of death by 34 percent compared to azags and placebos.
(Sina Pharmaceutical News) Xinda Bio Class 1 new drug IBI112 start phase I clinical recently, Thyda Biology in the drug clinical trial registration and information publicity platform registration launched a class 1 new drug IBI112 in health subjects of single-dose administration phase I clinical research.
the main purpose of the study was to evaluate the safety and tolerance of Chinese health subjects after single doses of off-the-cortective injection or intravenous giving IBI112.
(Pharmaceutical Rubik's Cube) regenerative meta-breakthrough first in class single resistance by the FDA priority review 12, regenerative meta announced that the FDA has accepted the evinacumab combined with other lipid-lowering drugs to treat pure heterogen familial hypercholesterolemia market application, and the application was granted priority review qualification.
evinacumab as a first in class is another milestone in the field of blood lipid reduction.
(Pharmaceutical Rubik's Cube) FDA accelerated approval of DMD Innovative Therapy THE FDA announced accelerated approval of the listing of Viltepso, a subsidiary of NS Pharma, a subsidiary of Japan's New Drug Co., Ltd., for the treatment of specific patients with Duchy muscular dystrophy (DMD).
confirmed that they carry DMD gene mutations that can be treated with exon 53 jumps.
is the second FDA-approved targeted treatment for patients with the mutation.
(Immediate Drug News) Seattle Genetics Targeted Anti-Cancer Drug Tukysa Combined Therapy has been approved by the TGA Seattle Genetics recently announced that the Australian Therapeutic Products Administration (TGA) has approved targeted anti-cancer drug Tukysa, co-cinnapressant and carptonine, for the treatment of patients who cannot be surgically removed and have previously underwent one or more anti-HER2 programs, including advanced or metastatic HER2-positive breast cancer patients, including those undergoing brain transfer.
(Bio Valley) Fosun Pharma Avaquopa tablets approved clinical Fosun Pharma issued a notice that the company's holding subsidiary Fosun Pharmaceutical Industry received the "Receiving Notice", its licensed Malay acid Avalanche pharma tablets for chronic immunocompetitive plate plate reduction adaptation was approved by the State Drug Administration clinical trial registration review.
(Fosun Pharma Announcement) Treasure Island anti-idydic pulmonary fibrosis class 1 innovative drug ZBD0276 tablets were approved for clinical trials on the 12th, Treasure Island announced that the company received the "Drug Clinical Trial Approval Notice" for the anti-idydypulmonary fibrosis class 1 innovative drug ZBD0276 clinical trial approval.
The product is the company and pharmaceutical Mingkangde according to the two sides signed a "class 1 new drug project technology development contract", and joint research and development of anti-idydypulmonary fibrosis class 1 innovative drugs, by treasure island has its own intellectual property rights.
(Treasure Island Announcement) domestic anti-AIDS class 1 new drugs "Azf tablets" to be included in the priority review CDE official website 12 shows that real life 1 new drugs "Azf tablets" listing applications to be included in the priority review, including the reasons for clinically urgent shortage of drugs, prevention and treatment of major infectious diseases and rare diseases and other diseases of innovative drugs and improved new drugs into the priority review process.
(CDE) targeted CD137 Lijin Bio1 new drugs in China declared clinical 12, CDE publicity, Lijin Biology submitted a class 1 bio-new drug LVGN6051 monoclonal antibody injection clinical trial application, and was accepted.
is a CD137 agitation antibody and is currently undergoing Phase 1 clinical trials in the United States.
(CDE) antibacterial drug eye dosage form first imitation competition fierce Noan Pharmaceuticals new entry 12, the latest CDE data show that Noan Pharmaceuticals' hydrochloric acid Moxisa Star eye drops 4 types of imitation market applications to be undertaken.
is a heavy variety of anti-bacterial drugs throughout the body.
only Ercon has been approved for import in the domestic market, with the product entering the Chinese market in 2018 and the National Health Insurance Directory in 2019.
(CDE) PD-1 antibody combined with TREM2 inhibitor Mice tumors completely subsided, researchers at the University of Washington School of Medicine enhanced the role of PD-1 antibodies by blocking TREM2 proteins in a new study published in Cell, eliminating tumors in mice.
findings point to a new combination therapy that could allow more cancer patients to benefit better from immunotherapy.
(Medical Rubik's Cube)